Therapeutic Options to Refractory Alopecia Areata

Article Sidebar

PDF
Published: Jan 10, 2023
DOI: https://doi.org/10.47191/ijmscrs/v3-i1-06
Keywords:
...

Main Article Content

Alejandra Jeraldine González Barajas
Universidad Autónoma de Guadalajara
Paola Chávez Contreras
Universidad Autónoma de Guadalajara

Abstract

Alopecia areata is a relapsing chronic condition that causes hair loss without leaving scars. Alopecia areata's clinical history varies; the condition may resolve spontaneously, persist, recur, or advance. Alopecia areata sufferers are treated in numerous ways, including: Information about the progression and prognosis of alopecia areata Consideration of medical treatment continuation; Treatment selection (for individuals who desire to continue treatment); Provision of psychological support resources; and Discussion of aesthetic possibilities.

Article Details

How to Cite
González Barajas, A. J. ., & Contreras, P. C. . (2023). Therapeutic Options to Refractory Alopecia Areata. International Journal of Medical Science and Clinical Research Studies, 3(1), 25–27. https://doi.org/10.47191/ijmscrs/v3-i1-06
Issue
Vol. 3 No. 1 (2023): Volume 03 Issue 01 January 2023
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Gao, Y., Huo, S., Sun, M., Zhang, C., Wang, J., Gao, J., ... & Lv, Y. (2022). Evaluation of several immune and inflammatory indicators and their association with alopecia areata. Journal of Cosmetic Dermatology, 21(7), 2995-3001.

II. Davey, L., Clarke, V., & Jenkinson, E. (2019). Living with alopecia areata: an online qualitative survey study. British Journal of Dermatology, 180(6), 1377-1389.

III. Moretz, D. (2021). OHSU Drug Effectiveness Review Project Summary Report–Atopic Dermatitis.

IV. Gilhar, A., Keren, A., & Paus, R. (2019). JAK inhibitors and alopecia areata. The Lancet, 393(10169), 318-319.

V. Winthrop, K. L., & Cohen, S. B. (2022). Oral surveillance and JAK inhibitor safety: The theory of relativity. Nature Reviews Rheumatology, 18(5), 301-304.

VI. Crowley, E. L., Fine, S. C., Katipunan, K. K., & Gooderham, M. J. (2019). The use of Janus kinase inhibitors in alopecia areata: a review of the literature. Journal of cutaneous medicine and surgery, 23(3), 289-297.

VII. Mackay-Wiggan, J., Jabbari, A., Nguyen, N., Cerise, J. E., Clark, C., Ulerio, G., ... & Clynes, R. (2016). Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI insight, 1(15).

VIII. Luo, Y., Alexander, M., Gadina, M., O’Shea, J. J., Meylan, F., & Schwartz, D. M. (2021). JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition. Journal of Allergy and Clinical Immunology, 148(4), 911-925.

IX. Olsen, E. A., Kornacki, D., Sun, K., & Hordinsky, M. K. (2020). Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study. Journal of the American Academy of Dermatology, 82(2), 412-419.

X. AREATA, A. 7th World Congress for Hair Research.

XI. Sachdeva, M., Witol, A., Mufti, A., Maliyar, K., & Yeung, J. (2021). Alopecia areata related paradoxical reactions in patients on dupilumab therapy: a systematic review. Journal of Cutaneous Medicine and Surgery, 25(4), 451-452.

XII. Olamiju, B., & Craiglow, B. G. (2021). Combination oral minoxidil and spironolactone for the treatment of androgenetic alopecia in adolescent girls. Journal of the American Academy of Dermatology, 84(6), 1689-1691.

XIII. Amor, K. T., Ryan, C., & Menter, A. (2010). The use of cyclosporine in dermatology: part I. Journal of the American Academy of Dermatology, 63(6), 925-946.

XIV. Messenger, A. G., McKillop, J., Farrant, P., McDonagh, A. J., Sladden, M., Hughes, J., ... & Mohd Mustapa, M. F. (2012). British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. British journal of dermatology, 166(5), 916-926.

XV. Gupta, P., Verma, K. K., Khandpur, S., & Bhari, N. (2019). Weekly azathioprine pulse versus betamethasone oral mini-pulse in the treatment of moderate-to-severe alopecia areata. Indian Journal of Dermatology, 64(4), 292.

XVI. Açıkgöz, G., Çalışkan, E., Tunca, M., Yeniay, Y., & Akar, A. (2014). The effect of oral cyclosporine in the treatment of severe alopecia areata. Cutaneous and Ocular Toxicology, 33(3), 247-252.

XVII. Rossi, A., Muscianese, M., Piraccini, B. M., Starace, M., Carlesimo, M., Mandel, V. D., ... & Fortuna, M. C. (2019). Italian Guidelines in diagnosis and treatment of alopecia areata.

XVIII. Ramos, P. M., Anzai, A., Duque-Estrada, B., Melo, D. F., Sternberg, F., Santos, L. D. N., ... & Mulinari-Brenner, F. (2021). Consensus on the treatment of alopecia areata–Brazilian Society of Dermatology. Anais Brasileiros de Dermatologia, 95, 39-52.

XIX. Ellis, C. N., Brown, M. F., & Voorhees, J. J. (2002). Sulfasalazine for alopecia areata. Journal of the American Academy of Dermatology, 46(4), 541-544.

XX. Nasimi, M., Ghandi, N., Abedini, R., Mirshamsi, A., Shakoei, S., & Seirafi, H. (2019). Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series. Archives of Dermatological Research, 311(8), 607-613.